SCHEMBL5209626

SCHEMBL5209626

CCOC(=O)C(C)(Cc1ccc(OCc2ccccc2)cc1)Oc1ccc(F)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.47
MAOA P21397 1/20 0.47
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PPARA Q07869 2/20 0.45
PPARG P37231 3/20 0.45
OPRK1 P41145 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MRGPRX4 Q96LA9 2/20 0.43
ALOX5 P09917 2/20 0.43
TSPO P30536 2/20 0.42
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210213 0.89 NR4A2 (0.49) MAOBLMNAL3MBTL1PPARAPPARG
SCHEMBL2807182 0.88 PPARG (0.55) MAOBLMNAL3MBTL1PPARAPPARG
SCHEMBL14176244 0.88 LMNA (0.54) MAOBLMNAL3MBTL1PPARAPPARG
SCHEMBL5122510 0.87 OPRK1 (0.49) MAOBMAOAPPARAPPARGOPRK1
SCHEMBL3992279 0.86 LMNA (0.46) MAOBLMNAL3MBTL1PPARAPPARG
SCHEMBL5209756 0.86 MRGPRX4 (0.53) MAOBLMNAL3MBTL1PPARAPPARG
SCHEMBL5208740 0.86 PPARA (0.62) MAOBMAOALMNAL3MBTL1PPARA
SCHEMBL5207761 0.86 PPARA (0.52) MAOBLMNAL3MBTL1PPARAPPARG
SCHEMBL5213397 0.85 PPARG (0.52) MAOBLMNAL3MBTL1PPARAPPARG
SCHEMBL5113057 0.85 RAB9A (0.52) MAOBLMNAL3MBTL1PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313717-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-10-17 EP disclosed
US-7176224-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2007-02-13 US disclosed
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY 2004-07-15 US disclosed
EP-1313717-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002016332-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARD, PPARG MAOB 3523/4885MAOA 2429/4885LMNA 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.